Floatz logo

TAMOXIFEN

Positive Nodes

National Cancer Institute (NCI)Small moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Positive Nodes cohort.

Asset / SponsorPhaseRating
Inno-206
Laura M. Spring, MD
Phase 3BB
Cyclophosphamide
Laura M. Spring, MD
Phase 3BB
Indocyanine Green
Isabelle Henskens
Phase 4BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3B

View all 24 →

Same molecule, other indications

TAMOXIFEN is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →